Metronidazol In Viaflo Baxter (Metronidazole)

Metronidazole enters susceptible bacteria and protozoa and is reduced by microbial enzymes to generate nitro radical anions. These reactive species damage DNA and inhibit nucleic acid synthesis, leading to loss of replication ability and cell death in anaerobic organisms.

The specific dose and infusion rate are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local treatment guidelines. Dosage should never be altered without medical direction.

Safety data for metronidazole in pregnancy are limited, and the drug is generally used only when the potential benefit outweighs the risk. It is excreted in breast milk, so breastfeeding mothers should consult their healthcare provider before use.

To request Metronidazol In Viaflo Baxter, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Metronidazole is a nitroimidazole that specifically targets anaerobic bacteria and certain protozoa, offering rapid bactericidal activity. Compared with broad‑spectrum beta‑lactams, it has a narrower spectrum but excellent tissue penetration and is often preferred for mixed anaerobic infections, especially when oral therapy is not feasible.

The product should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution, and use it within the time frame specified on the label after removal from refrigeration.

Metronidazol In Viaflo Baxter is supplied as an intravenous solution. It is administered by slow infusion into a vein under the supervision of qualified healthcare professionals, following aseptic technique and the infusion rate prescribed by the treating physician.

Serious risks include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, neutropenia, and hepatic dysfunction. Patients should be monitored for neurological symptoms, skin reactions, and liver function abnormalities during treatment.

Patients with known hypersensitivity to metronidazole or other nitroimidazoles should avoid the product. Caution is advised in individuals with severe hepatic or renal impairment, those taking interacting medications such as warfarin, lithium, or disulfiram, and pregnant or breastfeeding women unless the benefit justifies the risk.